Anna Ordyszewska

Anna Ordyszewska

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2019 in RSC Advances
Verified
Journal Article
Open access
PDF file
NSNatalia Szynkiewicz
Natalia Szynkiewicz
AOAnna Ordyszewska
Anna Ordyszewska
Jarosław ChojnackiJarosław Chojnacki
Jarosław Chojnacki
RGRafał Grubba
Rafał Grubba
We present the activation of CO2 by aminophosphinoboranes along with the mechanism of CO2 phosphinoboration.

3 March 2021 in Inorganic Chemistry
Verified
Journal Article
Open access
NSNatalia Szynkiewicz
Natalia Szynkiewicz
AOAnna Ordyszewska
Anna Ordyszewska
JCJarosław Chojnacki
Jarosław Chojnacki
RGRafał Grubba
Rafał Grubba
Herein, we present the first example of the activation of small molecules by P–B–P bond systems. The reactivity study involves reactions of two selected diphosphinoboranes, (t-Bu2P)2BPh (1′) and (Cy2P)2BNiPr2 (2), that differ in terms of their structural and electronic properties for the activation of dihydrogen, carbon dioxide, and phenyl isocyanate. Diphosphinoborane 1′ activates H2 under very mild conditions in the absence of a catalyst with the formation of the dimer (t-Bu2PB(Ph)H)2 and t-Bu2PH. Conversely, diphosphinoborane 2 did not react with H2 under the same conditions. The reaction of 1′ with CO2 led to the formation of a compound with an unusual structure, where two phosphinoformate units were coordinated to the PhBOBPh moiety. In addition, 2 reacted with CO2 to insert two CO2 molecules into the P–B bonds of the parent diphosphinoborane. Both diphosphinoboranes activated PhNCO, yielding products resulting from the addition of two and/or three PhNCO molecules and the formation of new P–C, B–O, B–N, and C–N bonds. The products of the activation of small molecules by diphosphinoboranes were characterized with nuclear magnetic resonance (NMR) and infrared (IR) spectroscopy, single-crystal X-ray diffraction, and elemental analysis. Additionally, the reaction mechanisms of the activation of small molecules by diphosphinoboranes were elucidated by theoretical methods.

22 June 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
AKAnita Kornicka
Anita Kornicka
KGKarol Gzella
Karol Gzella
KGKatarzyna Garbacz
Katarzyna Garbacz
MJMałgorzata Jarosiewicz
Małgorzata Jarosiewicz
MGMaria Gdaniec
Maria Gdaniec
AOAnna Ordyszewska
Anna Ordyszewska
A series of 2-(1H-indol-2-yl)-3-acrylonitrile derivatives, 2a–x, 3, 4a–b, 5a–d, 6a–b, and 7, were synthesized as potential antitumor and antimicrobial agents. The structures of the prepared compounds were evaluated based on elemental analysis, IR, 1H- and 13NMR, as well as MS spectra. X-ray crystal analysis of the representative 2-(1H-indol-2-yl)-3-acrylonitrile 2l showed that the acrylonitrile double bond was Z-configured. All compounds were screened at the National Cancer Institute (USA) for their activities against a panel of approximately 60 human tumor cell lines and the relationship between structure and in vitro antitumor activity is discussed. Compounds of interest 2l and 5a–d showed significant growth inhibition potency against various tumor cell lines with the mean midpoint GI50 values of all tests in the range of 0.38–7.91 μM. The prominent compound with remarkable activity (GI50 = 0.0244–5.06 μM) and high potency (TGI = 0.0866–0.938 μM) against some cell lines of leukemia (HL-60(TB)), non-small cell lung cancer (NCI-H522), colon cancer (COLO 205), CNS cancer (SF-539, SNB-75), ovarian cancer ((OVCAR-3), renal cancer (A498, RXF 393), and breast cancer (MDA-MB-468) was 3-[4-(dimethylamino)phenyl]-2-(1-methyl-1H-indol-2-yl)acrylonitrile (5c). Moreover, the selected 2-(1H-indol-2-yl)-3-acrylonitriles 2a–c and 2e–x were evaluated for their antibacterial and antifungal activities against Gram-positive and Gram-negative pathogens as well as Candida albicans. Among them, 2-(1H-indol-2-yl)-3-(1H-pyrrol-2-yl)acrylonitrile (2x) showed the most potent antimicrobial activity and therefore it can be considered as a lead structure for further development of antimicrobial agents. Finally, molecular docking studies as well as drug-likeness and ADME profile prediction were carried out.

18 July 2019 in Dalton Transactions
Verified
Journal Article
Closed access
PDF file
AOAnna Ordyszewska
Anna Ordyszewska
NSNatalia Szynkiewicz
Natalia Szynkiewicz
EPEmil Perzanowski
Emil Perzanowski
Jarosław ChojnackiJarosław Chojnacki
Jarosław Chojnacki
AWAleksandra Wiśniewska
Aleksandra Wiśniewska
RGRafał Grubba
Rafał Grubba
We present a series of amino- and aryl(diphosphino)boranes R2PB(R′′)PR′2, where R2P, R′2P = tBu2P, tBuPhP, Ph2P, Cy2P, and R′′ = iPr2N, Ph, which were obtained via the metathesis reaction of iPr2NBBr2 or PhBBr2 with selected lithium phosphides. The structures of isolated diphosphinoboranes were characterized in the solid state and in solution by means of X-ray diffraction and NMR spectroscopy, respectively. The utility of these P–B–P species as ligands for transition metal complexes was tested in the reaction with [(COD)PtMe2]. Moreover, we carried out DFT calculations to elucidate bonding interactions and philicity of the reactive centers as well as to analyze conformations of the studied species. Electronic and steric properties of substituents on P and B atoms were found to have a strong influence on the structures of the obtained compounds. Three main types of diphosphinoboranes were distinguished, based on the strength of P–B π-interaction within the molecule: (i) application of strong electron-donating substituents on P-atoms and electron-accepting phenyl groups on B atoms led to the structure with one double PB and one single P–B bond and diverse planar and pyramidal geometry of phosphanyl groups; (ii) reduction of the donor ability of phosphanyl groups gave diphosphanylboranes with delocalized P–B–P π-interactions; (iii) introduction of amino groups with strong donor abilities on B atoms canceled P–B π-interactions and allowed compounds with two very long P–B bonds and two pyramidal phosphanyl groups to be obtained.

27 February 2022 in Inorganic Chemistry
Verified
Journal Article
Open access
AOAnna Ordyszewska
Anna Ordyszewska
NSNatalia Szynkiewicz
Natalia Szynkiewicz
JCJarosław Chojnacki
Jarosław Chojnacki
RGRafał Grubba
Rafał Grubba
Herein, we present the synthesis of the first fully characterized monomeric triphosphinoboranes. The simple reaction of boron tribromide with 3 equiv of bulky lithium phosphide tBu2PLi yielded triphosphinoborane (tBu2P)3B. Triphosphinoboranes with diversified phosphanyl substituents were obtained via a two-step reaction, in which isolable bromodiphosphinoborane (tBu2P)2BBr is first formed and then reacts with 1 equiv of less bulky phosphide R2PLi (R2P = Cy2P, iPr2P, tBuPhP, or Ph2P). By utilizing this method, we obtained a series of triphosphinoboranes with the general formula (tBu2P)2BPR2. On the basis of structural and theoretical studies, two main types of triphosphinoborane structures can be distinguished. In the first type, all three electron lone pairs interact with the formally empty p orbital of the central boron atom, resulting in delocalized π bonding, whereas in the second type, one localized P═B bond and two P–B bonds are observed. The Lewis acidic–basic properties of triphosphinoboranes during the reaction of (tBu2P)2BPiPr2 with H3B·SMe2 were analyzed. The P–B bond-containing compound mentioned above not only formed an adduct with BH3 but also activated the B–H bond of the borane molecule, resulting in the incorporation of the BH2 unit into two phosphorus atoms and migration of a hydride to the boron atom of the parent triphosphinoborane. The structures of the triphosphinoboranes were confirmed by single-crystal X-ray analysis, multinuclear nuclear magnetic resonance spectroscopy, and elemental analysis.

6 March 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Łukasz BalewskiŁukasz Balewski
Łukasz Balewski
IIIwona Inkielewicz-Stępniak
Iwona Inkielewicz-Stępniak
MGMaria Gdaniec
Maria Gdaniec
KTKatarzyna Turecka
Katarzyna Turecka
Anna HeringAnna Hering
Anna Hering
AKAnita Kornicka
Anita Kornicka
Background/Objectives: Recently, there has been great interest in metallopharmaceuticals as potential anticancer agents. In this context, presented studies aim to synthesize and evaluate of two copper(II) complexes derived from phthalazine- and imidazoline-based ligands against on three human cancer cell lines: cervix epithelial cell line (HeLa), breast epithelial-like adenocarcinoma (MCF-7), and triple–negative breast epithelial cancer cell line (MDA-MB-231), as well as non-tumorigenic cell line (HDFa). Moreover their antimicrobial, and antioxidant properties were assessed. Methods: The synthetized compounds—both free ligands L1, L2, L3 and copper(II) complexes C1 and C2—were characterized by elemental analysis, infrared spectroscopy. Additionally, a single-crystal X-ray diffraction studies we performed for free ligand L3 and its copper(II) complex C2. The stability of Cu(II)-complexes C1 and C2 was evaluated by UV-Vis spectroscopy. The cytotoxic potency of free ligands and their copper(II) complexes was estimated on HeLa, MCF-7, MDA-MB-231, as well as non-cancerous HDFa by use of an MTT assay after 48 h of incubation. Moreover, the antimicrobial activity of ligands L1 and L3 and their copper(II) complexes C1 and C2 was evaluated using reference strains of the following bacteria and yeasts: Staphylococcus aureus, Escherichia coli, and Candida albicans. The free radical scavenging properties of free ligands L1, L3 and the corresponding copper(II) complexes C1, C2 was tested with two colorimetric methods—ABTS, DPPH, and reduction ability assay (FRAP). Additionally, the ADME webtool was used to assess the drug-likeness of the synthesized compounds, as well as their physicochemical and pharmacokinetic properties. Results: Copper(II) complex C2 exhibited antitumor properties towards MDA-MB-231 compared with Cisplatin (cancer cell viability rate of 23.6% vs. 22.5%). At a concentration of 200 μg/mL, complexes C1 and C2 were less cytotoxic than the reference Cisplatin against a normal, non-cancerous skin fibroblast cell line (HDFa). According to in vitro tests, C2 reduced the viability of HeLa, MCF-7, and MDA-MB-231 cells by about 57.5–81.2%. It was evident that all compounds were devoid of antibacterial or antifungal activity. In vitro assays revealed that a moderate antiradical effect was observed for free ligand L1 containing phthalazin-1(2H)-imine in the ABTS radical scavenging assay (IC50 = 23.63 µg/mL). Conclusions: The anticancer studies revealed that the most potent compound was copper(II) complex C2 bearing a phthalazin-1(2H)-one scaffold. None of the tested compounds showed antimicrobial or antifungal activity. This feature seems to be beneficial in terms of their potential uses as anticancer agents in the future. In vitro antiradical assays revealed that a moderate antioxidant effect was observed only for free ligand L1 containing phthalazin-1(2H)-imine.